A
References

BVGH (BIO Ventures for Global Health). 2006. Advance market commitments to stimulate industry investment in global health product development. http://bvgh.org/LinkClick.aspx?fileticket=W_5VAgleR8k%3d&tabid=91 (accessed March 18, 2010).

Center for Arms Control and Non-Proliferation: Scientists working group on biological and chemical weapons. 2010. Biological Threats: A Matter of Balance. Statement released January 26, 2010. http://www.armscontrolcenter.org/policy/biochem/articles/biological_threats_a_matter_of_balance (accessed March 8, 2010).

FDA (Food and Drug Administration). 2004. Innovation or stagnation: Challenge and opportunity on the critical path to new medical products. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathIniative/CriticalPathOpportunitiesReports/UCM113411.pdf (accessed March 4, 2010).

FDA. 2007. FDA science and mission at risk. Report of the Subcommittee on Science and Technology. http://www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4329b_02_01_FDA%20Report%20on%20Science%20and%20Technology.pdf (accessed March 9, 2010).

Graham, B., and J. Talent. 2009. Bioterrorism: Redefining prevention. Biosecurity and Bioterrorism: Biodefense strategy, practice, and science. 7(2):125–126. http://www.liebertonline.com/doi/pdfplus/10.1089/bsp.2009.0610?cookieSet=1 (accessed March 15, 2010).

IOM (Institute of Medicine). 2008. The U.S. commitment to global health: Recommendations for the new Administration. Washington, DC: The National Academies Press.

IOM. 2009. Venture philanthropy strategies to support translational research: Workshop summary. Washington, DC: The National Academies Press.

IOM and NRC (National Research Council). 2004. Giving full measure to countermeasures: Addressing problems in the DoD program to develop medical countermeasures against biological warfare agents. Washington, DC: The National Academies Press.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 57
A References BVGH (BIO Ventures for Global Health). 2006. Advance market com- mitments to stimulate industry investment in global health prod- uct development. http://bvgh.org/LinkClick.aspx?fileticket=W_5 VAgleR8k%3d&tabid=91 (accessed March 18, 2010). Center for Arms Control and Non-Proliferation: Scientists working group on biological and chemical weapons. 2010. Biological Threats: A Matter of Balance. Statement released January 26, 2010. http://www.armscontrolcenter.org/policy/biochem/articles/ biological_threats_a_matter_of_balance (accessed March 8, 2010). FDA (Food and Drug Administration). 2004. Innovation or stagnation: Challenge and opportunity on the critical path to new medical products. http://www.fda.gov/downloads/ScienceResearch/ SpecialTopics/CriticalPathIniative/CriticalPathOpportunities Reports/UCM113411.pdf (accessed March 4, 2010). FDA. 2007. FDA science and mission at risk. Report of the Subcommit- tee on Science and Technology. http://www.fda.gov/ohrms/ dockets/AC/07/briefing/2007-4329b_02_01_FDA%20Report%2 0on%20Science%20and%20Technology.pdf (accessed March 9, 2010). Graham, B., and J. Talent. 2009. Bioterrorism: Redefining prevention. Biosecurity and Bioterrorism: Biodefense strategy, practice, and science.7(2):125–126. http://www.liebertonline.com/doi/pdfplus/ 10.1089/bsp.2009.0610?cookieSet=1 (accessed March 15, 2010). IOM (Institute of Medicine). 2008. The U.S. commitment to global health: Recommendations for the new Administration. Washing- ton, DC: The National Academies Press. IOM. 2009. Venture philanthropy strategies to support translational re- search: Workshop summary. Washington, DC: The National Academies Press. IOM and NRC (National Research Council). 2004. Giving full measure to countermeasures: Addressing problems in the DoD program to develop medical countermeasures against biological warfare agents. Washington, DC: The National Academies Press. 57

OCR for page 57
58 EMERGENCY MEDICAL COUNTERMEASURES ENTERPRISE LSE (The London School of Economics and Political Science). 2010. Policies and incentives for promoting innovation in antibiotic re- search. http://www2.lse.ac.uk/newsAndMedia/news/archives/2009/09/ antibiotics.aspx (accessed March 14, 2010). Matheny, J., M. Mair, and B. Smith. 2008. Cost/success projections for U.S. biodefense counter-measure development. Nature Biotech- nology 26(9):981–983. Melese, T., S. M. Lin, J. L. Chang, and N. H. Cohen. 2009. Open innova- tion networks between academia and industry: An imperative for breakthrough therapies. Nature Medicine 15:502–507. NBSB (National Biodefense Science Board). 2010a. Where are the Countermeasures? Protecting America’s Health From CBRN Threats. http://www.hhs.gov/aspr/barda/documents/phemceimpl plan_041607final.pdf (accessed May 17, 2010). NBSB. 2010b. Optimizing industrial involvement in medical counter- measure development. http://www.hhs.gov/aspr/omsph/nbsb/ nbsbrpt-2010.pdf (accessed March 2, 2010). PhRMA. 2010. R&D investment by U.S. biopharmaceutical companies remains strong despite ongoing economic challenges. http://www.phrma.org/news/news/rd_investment_us_biopharma ceutical_companies_remains_strong_despite_ongoing_economic _chall (accessed March 30, 2010) Wolf, M. C., A. N. Freiberg, T. Zhang, A. Akyol-Ataman, A. Grock, et al. 2010. A broad-spectrum antiviral targeting entry of enveloped viruses. Proceedings of the National Academy of Sciences 107(7):3157–3162.